In addition, ipragliflozin reportedly reduces body fat mass by increasing lipolysis and fatty acid oxidation but not lean mass or bone mineral content in high‐fat diet‐induced obese rats (Yokono et al., 2014), and reverses abnormal regulation of appetite‐regulating hormones, such as neuropeptide Y and ghrelin, which are strongly correlated with obesity and lipid abnormalities (Tahara, Kondo, Takasu, & Tomiyama, 2018). This evidence concerns the gene NPY and obesity due to melanocortin 4 receptor deficiency.